
Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the emergence of regorafenib (Stivarga) and how it fits into the treatment of hepatocellular carcinoma (HCC).

Your AI-Trained Oncology Knowledge Connection!


Published: January 14th 2017 | Updated: